Clinical trial NCT05584930: Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
Official title: Evaluation of Serum Clusterin and Serum PTX3 Assay During Febrile Aplasia in Children Treated in Pediatric Oncology
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer Childhood
Febrile Neutropenia
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2022-10-18
Enrollment: 55
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Febrile aplasia is a common occurrence in children/adults treated with chemotherapy for malignant blood diseases or solid cancers.

This acquired deficiency of immunity mainly causes susceptibility to bacterial and fungal infections, pathogens normally recognized by specific receptors of innate immunity (Pattern Recognition Receptor, PRR).

Thus, the febrile episodes in the context of post-chemotherapy neutropenia can be bacterial or fungal etiology, but can also frequently be related to viral infections, toxic phenomena or other etiologies. In the absence of a discriminating marker, treatment for all these children is based on early, broad-spectrum antibiotic therapy in hospital. Septic shock or even death by refractory septic shock remain, even if they are rare, real complications in pediatric oncology, requiring discriminatory markers for effective management, While trying to reduce the number and duration of hospitalizations for children at low risk for severe febrile aplasia.

It is therefore necessary to identify other markers allowing the earliest possible classification of episodes of febrile aplasia.

A previous study, conducted by our team, PTX3 and febrile aplasia, studied pentraxin 3 (PTX3), a soluble PRR of the pentraxin family that plays a key role in immune surveillance against pathogens. Preliminary results obtained from samples from a cohort of patients treated in adult hematology and pediatric onco-hematology support a prognostic character of PTX3 in the severity of aplasia, with higher elevations of serum protein during episodes of severe sepsis or septic shock (ongoing analyses and interpretations for the adult population). The available data to date on the pediatric cohort are insufficient to conclude on the value of using PTX3. The investigators therefore wish to create a new paediatric cohort, in order to evaluate the PTX3 levels for the paediatric population and also to perform the assay of a new marker, clusterin.

Clusterin (CLU) is an extracellular chaperone protein of constitutive expression. The Innate Immunity team of the National Institute of Health and Medical Research (INSERM) "1307-Scientific Research National Center (CNRS) 6075" unit has shown that Clu binds to extracellular histones and inhibits their inflammatory, thrombotic and cytotoxic properties. The investigators also observed (i) that in adults without severe sepsis neutropenics, low serum levels of Clu at intake and lack of normalization of rates are associated with higher mortality and (ii) Clu levels are inversely correlated with circulating histone levels. All these data suggest that Clu would have a protective role for histone-induced lesions during sepsis independently of antibiotic treatment, opening an innovative therapeutic pathway in the management of severe sepsis.

CluPPFeN is based on the hypothesis that, in a pediatric population with episodes of febrile aplasia, serum Clu and serum PTX3 levels would discriminate between febrile episodes caused by bacterial infection and other etiologies and, As a result, would reduce the consumption of antibiotics, which provide resistance, and the length of hospitalization.

Detailed description: -Primary objective :

Evaluate serum levels CLU levels during febrile neutropenia in children followed for cancer.

-Secondary objective :

1. Evaluate serum levels of CLU at the beginning of non-febrile aplasia and during a possible 2nd febrile peak
2. Evaluate serum PTX3 levels during febrile neutropenia in children followed for cancer
3. Explore the association between CLU, PTX3 and the severity of the aplasia episode
4. Evaluate the association between CLU and PTX3 levels and the type of pathogen found during febrile aplasia
5. Exploration of the diagnostic contribution of CLU and PTX3 in relation to other known parameters of inflammation (including C reactive protein (CRP), procalcitonin (PCT), fibrinogen, interleukin 1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-α), CXCL8, IL17)
6. Exploration of genetic polymorphisms predisposing to bacterial and fungal infections (including PTX3 and CLU gene polymorphisms) in the context of febrile aplasia

Eligibility criteria: Inclusion Criteria:

* Child under 18 years
* Hospitalized for chemotherapy leading to febrile aplasia
* Signature of the informed consent of the parents or holder of parental authority and consent of the patient

Exclusion Criteria:

* Expected non aplasing chemotherapy
* Child with less than 5 kg body weight at inclusion

Primary outcomes:
measure: Evaluate serum CLU levels during febrile neutropenia in children followed for cancer
timeFrame: At inclusion
measure: Evaluate serum CLU levels during febrile neutropenia in children followed for cancer
timeFrame: up to 2 months
Secondary outcomes:
measure: Evaluate serum levels of CLU at the beginning of non-febrile aplasia and during a possible 2nd febrile peak.
timeFrame: up to 2 months
measure: Evaluate serum PTX3 levels during febrile neutropenia in children followed for cancer
timeFrame: up to 2 months
Other outcomes:
Locations:
city: Angers
country: France
facility: University Hospital of Angers
Study officials:
affiliation: UH Angers
name: Coralie MALLEBRANCHE, Dr
role: PRINCIPAL_INVESTIGATOR
References: